Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Clinical Trial of Olutasidenib in Patients With Acute Myeloid Leukemia

This clinical trial is a multicenter, single-arm, open-label study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of olutasidenib administered orally twice daily under fasting conditions for one cycle of 28 days in at least 3 Japanese patients with relapsed or refractory IDH1 mutation-positive AML.

Participants needed: 3
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Kissei Pharmaceutical Co., Ltd.Updated: May 27, 2026Locations: 1
Eligibility criteria

Japanese patients who personally provide written informed consent to participate... [+3]

Patients with IDH2 mutations or patients with a history of IDH2 inhibitor treatm... [+2]

Status: Recruiting

Special Drug Use-results Survey for Long-term Use(Avacopan)

The purpose of this survey is evaluating the safety and efficacy of long-term administration of avacopan for Japanese patients with microscopic polyangiitis or granulomatosis with polyangiitis under actual conditions of use.

Participants needed: 250
Trial details
Biological sex: AllType: ObservationalSponsor: Kissei Pharmaceutical Co., Ltd.Updated: Jan 17, 2025Locations: 1Duration: 2 Years
Eligibility criteria

Patients with granulomatosis with polyangiitis or microscopic polyangiitis who a...

Status: Recruiting

Special Drug Use-results Survey for Long-term Use (Fostamatinib)

The purpose of this survey is evaluating the safety and efficacy of long-term administration of fostamatinib for Japanese patients with chronic idiopathic thrombocytopenic purpura under actual conditions of use.

Participants needed: 149
Trial details
Biological sex: AllType: ObservationalSponsor: Kissei Pharmaceutical Co., Ltd.Updated: Jan 3, 2025Locations: 1Duration: 18 Months
Eligibility criteria

Patients with chronic idiopathic thrombocytopenic purpura who are treatment with...